View in EDS PDF Full Text

Successful treatment of MAP2K1 mutant stage IV-M1d melanoma with trametinib plus low-dose dabrafenib: a case report.

Saved in:
Bibliographic Details
Title: Successful treatment of MAP2K1 mutant stage IV-M1d melanoma with trametinib plus low-dose dabrafenib: a case report.
Authors: Dirven I; Department of Medical Oncology, Universitair Ziekenhuis Brussel (UZ Brussel) and Vrije Universiteit Brussel (VUB), Brussels, Belgium., Calliauw E; Department of Medical Oncology, Universitair Ziekenhuis Brussel (UZ Brussel) and Vrije Universiteit Brussel (VUB), Brussels, Belgium., Awada G; Department of Medical Oncology, Universitair Ziekenhuis Brussel (UZ Brussel) and Vrije Universiteit Brussel (VUB), Brussels, Belgium., Vounckx M; Department of Medical Oncology, Universitair Ziekenhuis Brussel (UZ Brussel) and Vrije Universiteit Brussel (VUB), Brussels, Belgium., Kessels JI; Department of Medical Oncology, Universitair Ziekenhuis Brussel (UZ Brussel) and Vrije Universiteit Brussel (VUB), Brussels, Belgium., Neyns B; Department of Medical Oncology, Universitair Ziekenhuis Brussel (UZ Brussel) and Vrije Universiteit Brussel (VUB), Brussels, Belgium.
Source: Frontiers in medicine [Front Med (Lausanne)] 2024 Sep 09; Vol. 11, pp. 1436774. Date of Electronic Publication: 2024 Sep 09 (Print Publication: 2024).
Publication Type: Case Reports; Journal Article
Journal Info: Publisher: Frontiers Media S.A Country of Publication: Switzerland NLM ID: 101648047 Publication Model: eCollection Cited Medium: Print ISSN: 2296-858X (Print) Linking ISSN: 2296858X NLM ISO Abbreviation: Front Med (Lausanne) Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 39314226
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Successful treatment of MAP2K1 mutant stage IV-M1d melanoma with trametinib plus low-dose dabrafenib: a case report.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Dirven+I%22">Dirven I</searchLink>; Department of Medical Oncology, Universitair Ziekenhuis Brussel (UZ Brussel) and Vrije Universiteit Brussel (VUB), Brussels, Belgium.<br /><searchLink fieldCode="AU" term="%22Calliauw+E%22">Calliauw E</searchLink>; Department of Medical Oncology, Universitair Ziekenhuis Brussel (UZ Brussel) and Vrije Universiteit Brussel (VUB), Brussels, Belgium.<br /><searchLink fieldCode="AU" term="%22Awada+G%22">Awada G</searchLink>; Department of Medical Oncology, Universitair Ziekenhuis Brussel (UZ Brussel) and Vrije Universiteit Brussel (VUB), Brussels, Belgium.<br /><searchLink fieldCode="AU" term="%22Vounckx+M%22">Vounckx M</searchLink>; Department of Medical Oncology, Universitair Ziekenhuis Brussel (UZ Brussel) and Vrije Universiteit Brussel (VUB), Brussels, Belgium.<br /><searchLink fieldCode="AU" term="%22Kessels+JI%22">Kessels JI</searchLink>; Department of Medical Oncology, Universitair Ziekenhuis Brussel (UZ Brussel) and Vrije Universiteit Brussel (VUB), Brussels, Belgium.<br /><searchLink fieldCode="AU" term="%22Neyns+B%22">Neyns B</searchLink>; Department of Medical Oncology, Universitair Ziekenhuis Brussel (UZ Brussel) and Vrije Universiteit Brussel (VUB), Brussels, Belgium.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101648047%22">Frontiers in medicine</searchLink> [Front Med (Lausanne)] 2024 Sep 09; Vol. 11, pp. 1436774. <i>Date of Electronic Publication: </i>2024 Sep 09 (<i>Print Publication: </i>2024).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Case Reports; Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Frontiers+Media+S%2EA%22">Frontiers Media S.A </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101648047 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>2296-858X (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%222296858X%22">2296858X </searchLink><i>NLM ISO Abbreviation: </i>Front Med (Lausanne) <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39314226
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3389/fmed.2024.1436774
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1436774
    Titles:
      – TitleFull: Successful treatment of MAP2K1 mutant stage IV-M1d melanoma with trametinib plus low-dose dabrafenib: a case report.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Dirven I
      – PersonEntity:
          Name:
            NameFull: Calliauw E
      – PersonEntity:
          Name:
            NameFull: Awada G
      – PersonEntity:
          Name:
            NameFull: Vounckx M
      – PersonEntity:
          Name:
            NameFull: Kessels JI
      – PersonEntity:
          Name:
            NameFull: Neyns B
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 09
              M: 09
              Text: 2024 Sep 09
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-print
              Value: 2296-858X
          Numbering:
            – Type: volume
              Value: 11
          Titles:
            – TitleFull: Frontiers in medicine
              Type: main
ResultId 1